博济医药：关于计提资产减值损失、信用减值损失及核销资产的公告

Core Viewpoint - The company, Boji Pharmaceutical, announced a comprehensive review of its assets, indicating potential impairment losses for certain assets as a precautionary measure [2] Asset Review Summary - The company and its subsidiaries conducted a thorough examination of various assets, including inventories, receivables, contract assets, fixed assets, construction in progress, intangible assets, goodwill, and assets held for sale [2] - The assessment revealed signs of impairment in some assets, leading the company to prepare for potential asset impairment losses [2] Impairment Losses - For the third quarter of 2025, the company recognized an asset impairment loss of 1,916,089.27 yuan and a credit impairment loss of 4,998,909.35 yuan [2] - The company also reversed impairment provisions amounting to 210,397.52 yuan and wrote off impairment provisions of 97,193.47 yuan [2]